Delving into the Latest Updates on Pacritinib with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ENPAXIQ, Epjevy, Pacritinib (USAN/INN)

+ [5]

Target

ALK2 x CSF-1R x FLT3 x IRAK1 x JAK2

Mechanism

ALK2 inhibitors(Activin receptor type-1 inhibitors), CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors)

+ [2]

Therapeutic Areas

Hemic and Lymphatic DiseasesOther DiseasesNeoplasms+ [1]

Active Indication

Primary MyelofibrosisThrombocytopeniaPost-essential thrombocythemia myelofibrosis+ [4]

Inactive Indication

Acute Myeloid LeukemiaAdult Acute Myeloblastic LeukemiaAdvanced Lymphoma+ [14]

Originator Organization

CTI BioPharma Corp.

Active Organization

Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum Ltd.Sobi, Inc.

+ [1]

Inactive Organization

S*BIO Pte Ltd.

Baxalta, Inc.

Drug Highest PhaseApproved

First Approval Date

US (28 Feb 2022),

Primary MyelofibrosisThrombocytopenia

RegulationFast Track (US), Orphan Drug (US), Priority Review (US), Accelerated Approval (US)

Login to view timeline

Structure

Molecular FormulaC28H32N4O3

InChIKeyHWXVIOGONBBTBY-ONEGZZNKSA-N

CAS Registry937272-79-2

This phase I trial tests the safety and side effects of pacritinib in combination with a Bruton's tyrosine kinase (BTK) inhibitor and how well it works in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Pacritinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. BTK inhibitors block a protein called BTK which is present on B-cell (a type of white blood cell) cancers such as mantle cell lymphoma at abnormal levels. This may help keep tumor cells from growing and spreading. Giving pacritinib in combination with a BTK inhibitor may be safe, tolerable and/or effective in treating patients with relapsed or refractory mantle cell lymphoma.

Start Date01 Nov 2025

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT06052618 / RecruitingPhase 2IIT

Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

Background:
Kaposi sarcoma herpesvirus (KSHV)-associated inflammatory cytokine syndrome (KICS) and KSHV-multicentric Castleman disease (MCD) occur in people living with HIV. These diseases cause severe inflammation that can be fatal if not treated.
Objective:
To test a drug (pacritinib) in people with KSHV-associated KICS or MCD.
Eligibility:
People aged 18 years and older with KSHV-associated KICS or MCD. They must have at least one symptom.
Design:
Participants will be screened. They will have a physical exam with blood tests and tests of their heart function. They will have imaging scans. Their ability to perform everyday tasks will be reviewed. In some participants who have Kaposi sarcoma (KS) with KICS or MCD, these individuals may need a bronchoscopy and/or endoscopy of the upper or lower intestine: A flexible tube with a camera and a light source will be inserted through the mouth or anus to see these structures and assess any KS.
Pacritinib is a capsule taken by mouth. Participants will take the drug twice a day, every day, for up to 24 weeks. They will write down each dose in a diary.
Participants will visit the clinic 3 times in the first 4 weeks. Their visits will taper to once every 4 weeks. Imaging scans, blood tests, and other tests will be repeated during these visits. Participants will give samples of saliva. They may opt to allow tissues samples to be taken from their skin and lymph nodes.
Participants will have follow-up visits 7 days and 30 days after their last dose of pacritinib. After that, they will visit the clinic every 3 months for up to 1 year. The physical exam and blood, heart, and imaging tests will be repeated at these visits.

Start Date21 Nov 2024

Sponsor / Collaborator

National Cancer Institute

NCT06303193 / Not yet recruitingPhase 1/2IIT

Phase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Background:
Myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) are blood disorders that can cause serious complications in children and adults. MDS and MDS/MPN can also progress to acute myeloid leukemia. Treatments for these disorders are risky and not always effective. Better treatments are needed.
Objective:
To test a study drug (pacritinib) in adults and children with MDS or MDS/MPN.
Eligibility:
Children (aged 12 to 17 years) and adults (aged 18 years and older) with MDS or MDS/MPN.
Design:
Participants will be screened. They will have a physical exam with blood tests. They will have tests of their heart function. They may have a bone marrow biopsy: An area over the hip will be numbed; a needle will be inserted to remove a sample of soft tissue from inside the hipbone.
Pacritinib is a capsule taken by mouth. All participants will take the study drug 2 times a day, every day, in 28-day cycles. They will write down the date and time they take each capsule. Doctors will assign varying dosages of the drug to different participants.
Participants will have clinic visits each week during cycle 1; every 2 weeks during cycle 2; and gradually increasing to every 3 months after cycle 13. Treatment will continue for up to 8 years.
Bone marrow biopsies, heart tests, and other tests will be repeated at intervals throughout the study. Participants will also fill out questionnaires about their quality of life, the symptoms of their disease, and other topics.

Start Date21 Nov 2024

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Pacritinib

Login to view more data

100 Translational Medicine associated with Pacritinib

Login to view more data

100 Patents (Medical) associated with Pacritinib

Login to view more data

174

Literatures (Medical) associated with Pacritinib

01 Dec 2024·Bioorganic Chemistry

Muti-target rationale design of novel substituted N-phenyl-2-((6-phenylpyridazin-3-yl)thio)acetamide candidates as telomerase/JAK1/STAT3/TLR4 inhibitors: In vitro and in vivo investigations

Article

Author: Alzahrani, Abdullah Yahya Abdullah ; El-Dessouki, Ahmed M. ; Shaldam, Moataz A ; Al-Karmalawy, Ahmed A ; Moussa, Sana Ben ; El-Dessouki, Ahmed M ; Mousa, Mai H A ; Saleh, Mohamed M ; Sharaky, Marwa ; Saleh, Mohamed M. ; Mousa, Mai H.A. ; Tawfik, Haytham O. ; Shaldam, Moataz A. ; Al-Karmalawy, Ahmed A. ; Tawfik, Haytham O

In this work, additional effort was applied to design new BIBR1532-based analogues with potential inhibitory activity against telomerase and acting as multitarget antitumor candidates to overcome the resistance problem. Therefore, novel substituted N-phenyl-2-((6-phenylpyridazin-3-yl)thio)acetamide candidates (4a-n) were synthesized. Applying the lead optimization strategy of the previously designed compound 8e; compound 4l showed an improved telomerase inhibition of 64.95 % and a superior growth inhibition of 79 % suggesting its potential use as a successful "multitarget-directed drug" for cancer therapy. Accordingly, compound 4l was further selected to evaluate its additional JAK1/STAT3/TLR4 inhibitory potentials. Compound 4l represented a very promising JAK1 inhibitory potential with a 0.46-fold change, compared to that of pacritinib reference standard (0.33-fold change). Besides, it showed a superior STAT3-inhibitory potential with a 0.22-fold change compared to sorafenib (0.33-fold change). Additionally, compound 4l downregulated TLR4 protein expression by 0.81-fold change compared to that of resatorvid (0.29-fold change). Also, molecular docking was performed to investigate the binding mode and affinity of the superior candidate 4l towards the four target receptors (telomerase, JAK1, STAT3, and TLR4). Furthermore, the therapeutic potential of compound 4l as an antitumor agent was additionally explored through in vivo studies involving female mice implanted with Solid Ehrlich Carcinoma (SEC). Remarkably, compound 4l led to prominent reductions in tumor size and mass. Concurrent enhancements in biochemical, hematologic, histopathologic, and immunohistochemical parameters further confirmed the suppression of angiogenesis and inflammation, elucidating additional mechanisms by which compound 4l exerts its anticancer effects.

01 Nov 2024·Clinical Lymphoma Myeloma and Leukemia

Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib

Article

Author: Buckley, Sarah ; Roman-Torres, Karisse ; Gagelmann, Nico ; Treskes, Philipp ; Scott, Bart ; Al-Ali, Haifa-Kathrin ; Vachhani, Pankit ; McLornan, Donal P ; Ali, Haris ; Bose, Prithviraj ; Gupta, Vikas

BACKGROUNDPacritinib is a JAK2/IRAK1/ACVR1 inhibitor that is approved in the United States for the treatment of patients with myelofibrosis who have a platelet count < 50 × 109/L. Phase 3 clinical studies of pacritinib included patients across a wide range of baseline platelet and hemoglobin levels.PATIENTS AND METHODSIn order to assess the impact of baseline blood counts on pacritinib efficacy, an analysis of efficacy outcomes by baseline platelet and hemoglobin levels was performed using data pooled from 2 Phase 3 studies of pacritinib in patients with MF (PERSIST-1 and PERSIST-2).RESULTSOf 276 patients evaluable for spleen response, spleen volume reduction occurred consistently across platelet subgroups (< 100 × 109/L or ≥ 100 × 109/L) and hemoglobin subgroups (< 8 g/dL, ≥ 8 to < 10 g/dL, or > 10 g/dL), with no diminution in treatment effect in patients with severe thrombocytopenia or anemia. Among 159 patients evaluable for symptoms response, improvement in total symptom score (TTS) was similar across platelet subgroups. A ≥ 50% improvement of TSS occurred more frequently in patients with baseline hemoglobin < 8 g/dL compared with those with baseline hemoglobin ≥ 8 to < 10 g/dL or > 10 g/dL. Patients with baseline hemoglobin < 8 g/dL also experienced improved hemoglobin sustained over 24 weeks, whereas subgroups with less severe anemia had stable hemoglobin levels over time. Symptom improvement as assessed using the Patient Global Impression of Change instrument was generally consistent across platelet and hemoglobin subgroups.CONCLUSIONPacritinib demonstrates consistent efficacy in patients with MF regardless of baseline platelet and hemoglobin counts.

01 Nov 2024·Biochemical and Biophysical Research Communications

High-throughput screening identified pacritinib as a promising therapeutic approach to overcome lenvatinib resistance in hepatocellular carcinoma by targeting IRAK1

Article

Author: Wang, Jiazhen ; Lin, Enhua ; Heng, Shan ; Chen, Xiaoyu ; Xu, Zihao ; Wu, Jianghao ; Gu, Hongyi ; Shan, Yunfeng ; Li, Changyu

Lenvatinib resistance presents a significant challenge in the clinical management of advanced hepatocellular carcinoma (HCC). To address this issue, we established lenvatinib resistant HCC cells and performed high-throughput screening using FDA-approved anti-cancer drug library. Through quantitative selective drug sensitivity scoring (sDSS), pacritinib, a well-known JAK inhibitor, emerged as the top candidate, displaying the highest sDSS score among 219 compounds. We further demonstrated that pacritinib reduced the viability of a panel of HCC cell lines in a dose-dependent manner, while exhibiting minimal effects on normal liver cells. Interestingly, pacritinib, but not other JAK inhibitors such as ruxolitinib, upadacitinib, or filgotinib, acted synergistically with lenvatinib in HCC cells. In lenvatinib-resistant HCC cells, pacritinib significantly decreased proliferation and induced apoptosis. Rescue studies using IL-1 receptor-associated kinase 1 (IRAK1) overexpression and knockdown revealed that pacritinib's effects are mediated through IRAK1, with minimal impact on normal liver cells. In a xenograft model of lenvatinib-resistant HCC, oral administration of pacritinib significantly reduced tumor size without affecting body weight. Immunohistochemical analysis of tumor sections revealed that pacritinib reduced Ki67 staining and phosphorylated IRAK1. Our findings suggest that pacritinib may be a promising therapeutic option for the treatment of advanced HCC, particularly in patients who have developed resistance to lenvatinib.

63

News (Medical) associated with Pacritinib

24 Oct 2024

·www.prnewswire.com

Sobi Q3 2024 report: Strong growth and significant pipeline momentum

STOCKHOLM, Oct. 24, 2024 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2024 Third Quarter 2024 Total revenue increased 33 per cent, 39 per cent at constant exchange rates, (CER)1, to SEK 6,894 M (5,168) Haematology revenue increased 18 per cent at CER to SEK 4,000 M (3,484), mainly driven by strong sales of Doptelet® of SEK 1,039 M (650), sales of Aspaveli®/Empaveli® of SEK 270 M (169) and launch sales of Altuvoct® of SEK 129 M (—) Immunology revenue increased 96 per cent at CER to SEK 2,583 M (1,400), driven by strong Beyfortus® royalty of SEK 1,478 M (263) and sales of Kineret® of SEK 699 M (600) Revenue from medicines in the strategic portfolio* grew by 113 per cent at CER to SEK 3,830 M (1,924) The adjusted EBITA margin1,2 was 43 per cent (30), excluding items affecting comparability (IAC)2. EBITA was SEK 2,923 M (1,443), corresponding to a margin of 42 per cent (28). EBIT was SEK 2,038 M (547) Earnings per share (EPS) before dilution was SEK 4.27 (0.30). Adjusted EPS before dilution1 was SEK 4.36 (0.54). Cash flow from operating activities was SEK 1,201 M (1,058) In August, Sobi and Apellis Pharmaceuticals announced positive topline results from the Phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN Outlook 2024 - Updated Revenue is anticipated to grow by a mid-teens percentage at CER (previously low double-digit) The adjusted EBITA margin is anticipated to be in the mid-30s percentage of revenue (unchanged) Click here for the Financial Summary. Alternative Performance Measures (APMs). Items affecting comparability (IAC). * The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant®, Vonjo® and Zynlonta®, and royalty on Sanofi's sales of Altuviiio® and Beyfortus. Investors, analysts, and the media are invited to a conference call on the same day at 14:00 CEST, 13:00 BST, and 08:00 EDT. The call will include a presentation of the results and a Q&A session. The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call. To participate in the conference call, please use the following dial-in details: Sweden: +46 8 5051 0031 United Kingdom: +44 207 107 06 13 United States: +1 631 570 56 13 For other countries, please find the details here. Sobi Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:00 CEST on 24 October 2024. Gerard Tobin Head of Investor Relations This information was brought to you by Cision The following files are available for download: SOURCE Swedish Orphan Biovitrum AB WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Financial StatementClinical ResultPhase 3Biosimilar

16 Jul 2024

·www.prnewswire.com

Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2024 STOCKHOLM, July 16, 2024 /PRNewswire/ -- Second Quarter 2024 Total revenue increased 12 per cent, 11 per cent at constant exchange rates, (CER), to SEK 5,442 M (4,872) Haematology revenue increased 13 per cent at CER to SEK 3,866 M (3,430), reflecting growth in all medicines, mainly driven by strong sales of Doptelet® excluding sales to China of SEK 928 M (567), sales of Vonjo® of SEK 347 M (36) and sales of Aspaveli®/Empaveli® of SEK 251 M (144) Immunology revenue increased 7 per cent at CER to SEK 1,277 M (1,179), driven by strong sales of Kineret® of SEK 745 M (661) and Gamifant® of SEK 522 M (491) Revenue from medicines in the strategic portfolio grew by 74 per cent at CER to SEK 2,219 M (1,258) The adjusted EBITA margin was 28 per cent (26), excluding items affecting comparability (IAC). EBITA was SEK 1,486 M (1,009), corresponding to a margin of 27 per cent (21). EBIT was SEK 612 M (413) Earnings per share (EPS) before dilution was SEK 0.66 (0.71). Adjusted EPS before dilution was SEK 0.72 (1.41). Cash flow from operating activities was SEK 2,329 M (357) Altuvoct® (efanesoctocog alfa) was EU approved for once-weekly treatment of haemophilia A Aspaveli was EU approved for use among treatment naïve adult patients with PNH Biologics license application to FDA initiated for SEL-212 for the potential treatment of chronic refractory gout Outlook 2024 - updated Revenue is anticipated to grow by low double-digit percentage at CER (previously high single-digit) The adjusted EBITA margin is anticipated to be in the mid-30s percentage of revenue (unchanged) The strategic portfolio includes Sobi's medicines Aspaveli/Empaveli, Doptelet excluding China, Gamifant, Vonjo and Zynlonta®, and royalty on Sanofi's sales on Altuviiio® and Beyfortus®. Investors, analysts and media are invited to participate in a conference call, which will include a presentation of the results and a Q&A session on the same day at 14:00 CEST. The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call. To participate in the conference call, please use the following dial-in details: Sweden: +46 8 5051 0031 United Kingdom: +44 207 107 06 13 United States: +1 631 570 56 13 For other countries, please find the details here. Sobi Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, on 16 July 2024 at 08:00 CEST. Gerard Tobin Head of Investor Relations This information was brought to you by Cision The following files are available for download:

Drug ApprovalBiosimilarFinancial Statement

16 Jul 2024

·www.prnewswire.com

Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2024 STOCKHOLM, July 16, 2024 /PRNewswire/ -- Second Quarter 2024 Total revenue increased 12 per cent, 11 per cent at constant exchange rates, (CER), to SEK 5,442 M (4,872) Haematology revenue increased 13 per cent at CER to SEK 3,866 M (3,430), reflecting growth in all medicines, mainly driven by strong sales of Doptelet® excluding sales to China of SEK 928 M (567), sales of Vonjo® of SEK 347 M (36) and sales of Aspaveli®/Empaveli® of SEK 251 M (144) Immunology revenue increased 7 per cent at CER to SEK 1,277 M (1,179), driven by strong sales of Kineret® of SEK 745 M (661) and Gamifant® of SEK 522 M (491) Revenue from medicines in the strategic portfolio grew by 74 per cent at CER to SEK 2,219 M (1,258) The adjusted EBITA margin was 28 per cent (26), excluding items affecting comparability (IAC). EBITA was SEK 1,486 M (1,009), corresponding to a margin of 27 per cent (21). EBIT was SEK 612 M (413) Earnings per share (EPS) before dilution was SEK 0.66 (0.71). Adjusted EPS before dilution was SEK 0.72 (1.41). Cash flow from operating activities was SEK 2,329 M (357) Altuvoct® (efanesoctocog alfa) was EU approved for once-weekly treatment of haemophilia A Aspaveli was EU approved for use among treatment naïve adult patients with PNH Biologics license application to FDA initiated for SEL-212 for the potential treatment of chronic refractory gout Outlook 2024 - updated Revenue is anticipated to grow by low double-digit percentage at CER (previously high single-digit) The adjusted EBITA margin is anticipated to be in the mid-30s percentage of revenue (unchanged) The strategic portfolio includes Sobi's medicines Aspaveli/Empaveli, Doptelet excluding China, Gamifant, Vonjo and Zynlonta®, and royalty on Sanofi's sales on Altuviiio® and Beyfortus®. Investors, analysts and media are invited to participate in a conference call, which will include a presentation of the results and a Q&A session on the same day at 14:00 CEST. The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call. To participate in the conference call, please use the following dial-in details: Sweden: +46 8 5051 0031 United Kingdom: +44 207 107 06 13 United States: +1 631 570 56 13 For other countries, please find the details here. Sobi Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, on 16 July 2024 at 08:00 CEST. Gerard Tobin Head of Investor Relations This information was brought to you by Cision The following files are available for download: SOURCE Swedish Orphan Biovitrum AB

Drug ApprovalBiosimilarFinancial Statement

100 Deals associated with Pacritinib

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11768	Pacritinib	-	DB11697

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Primary Myelofibrosis	US	Swedish Orphan Biovitrum Ltd.	28 Feb 2022
Thrombocytopenia	US	Swedish Orphan Biovitrum Ltd.	28 Feb 2022

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Post-essential thrombocythemia myelofibrosis	Phase 1	NZ	CTI BioPharma Corp.	01 Jan 2013
Post-essential thrombocythemia myelofibrosis	Phase 1	NL	CTI BioPharma Corp.	01 Jan 2013
Post-essential thrombocythemia myelofibrosis	Preclinical	BE	CTI BioPharma Corp.	01 Jan 2013
Primary Myelofibrosis	Preclinical	NL	CTI BioPharma Corp.	01 Jan 2013
Primary Myelofibrosis	Preclinical	BE	CTI BioPharma Corp.	01 Jan 2013
Post-essential thrombocythemia myelofibrosis	Discovery	NL	CTI BioPharma Corp.	01 Jan 2013
Post-essential thrombocythemia myelofibrosis	Discovery	BE	CTI BioPharma Corp.	01 Jan 2013
Post-essential thrombocythemia myelofibrosis	Discovery	NZ	CTI BioPharma Corp.	01 Jan 2013
Primary Myelofibrosis	Discovery	BE	CTI BioPharma Corp.	01 Jan 2013
Primary Myelofibrosis	Discovery	NL	CTI BioPharma Corp.	01 Jan 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2024	Not Applicable	Myelofibrosis	-	Pacritinib	mnodxlryef(faqnikkxns) = pzyyoudblb bzcscphohz (gyipsoklei, 63.2 - 99.0) View more	-	08 Dec 2024
NCT01773187 \| NCT02055781 \| NCT04884191 (PERSIST-1, PERSIST-2, PAC203, ASH2024)	Phase 2/3	serum albumin \| cholesterol	484	Pacritinib 400 mg QD	(rzuifsivts) = bvjwdhauzf netfjvbxvc (mprrbpupxp, -1.3 to +3.14)	Positive	08 Dec 2024
SOHO2024	Not Applicable	Myelofibrosis	-	Momelotinib	sfusolohci(bazecorxie) = Common reasons for stopping MOM/PAC were adverse events (n=3; AKI, diarrhea, rash) nchsgkisft (ueedyfkrwq ) View more	-	04 Sep 2024
				Pacritinib
SOHO2024	Not Applicable	Myelofibrosis	-	Pacritinib 200 mg twice daily	(pdluhgahci) = xtqjkkzhfc lomdcivzmw (pwzhocwuxd ) View more	-	04 Sep 2024
				Best Available Therapy (BAT)	(pdluhgahci) = wfblwvwref lomdcivzmw (pwzhocwuxd ) View more
NCT02055781 (PERSIST-2, SOHO2024)	Phase 3	Anemia \| Thrombocytopenia \| Myelofibrosis	-	Pacritinib 200 mg twice daily	nbxvhycuny(jrlaqiwffa) = ohppyuxguc wiukmwdqte (zbeknpmefm ) View more	Positive	04 Sep 2024
				Best Available Therapy (BAT)	nbxvhycuny(jrlaqiwffa) = tqldhwulso wiukmwdqte (zbeknpmefm ) View more
SOHO2024	Not Applicable	Myelofibrosis	-	Pacritinib	(rdjfydyjri) = yshedescvx nuewfwpmqi (gakblgebnf, 7.9 - 10.3) View more	-	04 Sep 2024
NCT04404361 (PRE-VENT, CTgov)	Phase 2	COVID-19 \| Neoplasms	200	Pacritinib (Pacritinib and SOC)	kvayvhwpqm(vqvyrkpzbk) = skgguygvnb zqgkhstbvx (soqgzffzsh, drtwcsdtlx - jagebqnrct) View more	-	05 Jun 2024
				Placebo (Placebo and SOC)	kvayvhwpqm(vqvyrkpzbk) = kieavwuopg zqgkhstbvx (soqgzffzsh, lhjntkeylz - oxrggkblav) View more
NCT02055781 (PERSIST-2, ASCO2024) Manual	Phase 3	Thrombocytopenia \| Myelofibrosis	92	Pacritinib	(ovhymngkiq) = imhfikjcyt kvyoirxkgz (rxhambduyz ) View more	Positive	24 May 2024
				Best Available Therapy (including Ruxolitinib)	(ovhymngkiq) = emnpbxlryr kvyoirxkgz (rxhambduyz ) View more
ASCO2024 Manual	Not Applicable	Myelofibrosis Third line	142	Pacritinib	(padqeiqpad) = qytjyyphtk yfqkfvweln (rgumefenlt, 56.8 - 79.0) View more	Positive	24 May 2024
NCT02055781 (PERSIST-2, ASCO2024) Manual	Phase 3	Myelofibrosis	93	Pacritinib	(pmdwgmxmhh) = vtonqumkok shqplmchcp (yxthazziek ) View more	Positive	24 May 2024
				Best Available Therapy (BAT)	(pmdwgmxmhh) = evblanuvfg shqplmchcp (yxthazziek ) View more